| Consensus molecular subtypes (CMS) as prognostic and predictive biomarkers of RAS wild-type (WT) metastatic colorectal cancer (mCRC): Pooled analysis of the randomized trials FIRE-1, FIRE-3, XELAVIRI, and PanaMa. |
|
|
| J Clin Oncol 42 (suppl 16) |
|
2024 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| doi.org/10.1200/JCO.2024.42.16_suppl.3529 |
|
|
| Pelareorep driven blood TIL expansion in patients with pancreatic, breast and colon cancer. |
|
|
| J Clin Oncol 42 (suppl 16) |
|
2024 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| doi.org/10.1200/JCO.2024.42.16_suppl.e14625 |
|
|
| Efficacy and safety of liposomal irinotecan (nal-IRI) plus fluorouracil (5-FU) and leucovorin (LV) versus 5-FU/LV alone for advanced biliary tract cancer (BTC) after progression on gemcitabine-based therapy: A pooled analysis of the NIFTY and NALIRICC trials. |
|
|
| Ann Oncol 35 (Supplement 2, 58P): 235 |
|
2024 |
|
Hepatobiliäre Tumoren
|
|
|
| doi.org/10.1016/j.annonc.2024.08.067 |
|
|
| Nanoliposomal Irinotecan With Fluorouracil and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Cholangiocarcinoma: A Phase II Study of the AIO Hepatobiliary-YMO Cancer Groups (NIFE-AIO-YMO HEP-0315) |
|
|
| J Clin Oncol 42(26): 3094-104 |
|
2024 |
|
Hepatobiliäre Tumoren
|
|
|
| doi.org/10.1200/JCO.23.01566 |
|
|
| Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial. |
|
|
| Lancet G&H 9: 734-44 |
|
2024 |
|
Hepatobiliäre Tumoren
|
|
|
| doi.org/10.1016/ S2468-1253(24)00119-5 |
|
|
| Nanoliposomal Irinotecan With Fluorouracil and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Cholangiocarcinoma: A Phase II Study of the AIO Hepatobiliary-YMO Cancer Groups (NIFE-AIO-YMO HEP-0315). |
|
|
| J Clin Oncol |
|
2024 |
|
Hepatobiliäre Tumoren
|
|
|
| ascopubs.org/doi/full/10.1200/JCO.23.01566 |
|
|
| Nal-IRI with 5-fluorouracil and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer, a phase 2 study of the AIO hepatobiliary and YMO cancer groups (NIFE-AIO-YMO HEP-0315) - updated survival and QoL results. |
|
|
| Oncol Res Treat 47 (suppl 1): 66 |
|
2024 |
|
Hepatobiliäre Tumoren
|
|
|
| doi.org/10.1159/000535363 |
|
|
| Steroid and antibiotic treatment are associated with diverse immunotherapy efficacy: A pooled analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC trials of the German AIO study group |
|
|
| Ann Oncol 35 (Supplement 2, 1067P): 707 |
|
2024 |
| doi.org/10.1016/j.annonc.2024.08.1125 |
|
|
| Progression-free and overall survival of patients with SCLC and ECOG performance status 0-1 – Data from the Clinical Research platform Into molecular testing, treatment and outcome of (non-) Small cell lung carcinoma Patients (CRISP; AIO-TRK-0315). |
|
|
| Oncol Res Treat 47(suppl 2): 199-200 (P448) |
|
2024 |
| doi.org/10.1159/000540557 |
|
|
| Predictors of Immune-Related Adverse Events in Immune Checkpoint Inhibitor Therapy – A pooled analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC studies of the German AIO study group. |
|
|
| Oncol Res Treat 47(suppl 2): 45 (V239) |
|
2024 |
| doi.org/10.1159/000540557 |
|
|
